큐리언트

115180KOSDAQ자연과학 및 공학 연구개발업

47.3 / 100

Reference Date: 2026-06-10

Financial Score11.0 / 40

News Sentiment21.3 / 25

Momentum5.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, Revenue is on a declining trend. Plunged 20.0% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Curient is a biotech company specializing in new drug development, established with government and international investments to advance Korea's pharmaceutical and biotech industry. Collaborating with institutions like the French Pasteur Institute and Germany's Max Planck Society, it focuses on infectious disease and oncology/immunology therapies. Partnering with MSD, it develops combination therapies with Keytruda, and reported consolidated sales of 92 billion KRW in 2024.

Number of Employees

32people

Average Salary

141.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 62.704.0Point

PBR

—Industry Average 3.243.5Point

ROE

-68.05Industry Average -32.093.5Point

2.1x industry avg (excellent)

Debt Ratio

48.23Industry Average 7.310.0Point

6.6x industry avg (risky)

Trend 2023~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼11.2% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼13.3% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -57.4% (declining, 3yr)

Detailed News Sentiment

3 totalPositive 3Neutral 0Negative 0Average Sentiment Score 85

Positive
유방암 약 내성 생기면 끝?… 큐리언트, 새 치료제 임상 2상 돌입
큐리언트의 새로운 유방암 치료제 임상 2상 시작으로 혁신적인 신약 개발 가능성이 높아져 긍정적 전망.
Positive
큐리언트 "모카시클립, 유방암 2상 첫 환자 투약"
큐리언트의 CDK4·6 저해 항암제 모카시클립이 유방암 환자 대상 첫 임상 투여를 성공적으로 완료하며 긍정적인 임상 진전을 보고했다.
Positive
큐리언트, 모카시클립 유방암 효능 검증(PoC) 본격화...임상 2상...
큐리언트의 모카시클립 유방암 치료제 임상 2상 첫 환자 투약 성공으로 긍정적인 임상 진행 신호.

Detailed Momentum

52-week position3.0Point

52w lower range (37%)

Current 25,450Won52-week high 50,90052-week low 9,950

1-month return0.0Point

1m -19.97% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral[기재정정]주식매수선택권행사2026-05-21
Neutral분기보고서 (2026.03)2026-05-15